Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer

PDF  |  How to cite

Oncotarget. 2018; 9:35284-35284. https://doi.org/10.18632/oncotarget.26254

Metrics: PDF 1293 views  |   ?  

Naiqing Xu1,2,3,*, Wenfeng Fang4,*, Libing Mu5, Yanna Tang4, Lei Gao2, Shengxiang Ren6, Dengfeng Cao7, Lixin Zhou8, Aiqun Zhang9, Deruo Liu10, Caicun Zhou6, Kwok- Kin Wong11, Lei Yu12, Li Zhang4 and Liang Chen1,2,3,13

1 Graduate School of Peking Union Medical College, Beijing, China
2 National Institute of Biological Sciences, Beijing, China
3 Chinese Academy of Medical Sciences, Beijing, China
4 Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, P. R. China
5 Tsinghua University School of Medicine, Beijing, China
6 Shanghai Pulmonary Hospital, Shanghai, China
7 Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, China
8 Peking University Cancer Hospital, Beijing, China
9 General Hospital of People’s Liberation Army, Beijing, China
10 Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China
11 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
12 Beijing Tongren Hospital, Capital Medical University, Beijing, China
13 National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China
* These author have contributed equally to this work

Published: October 16, 2018

This article has been corrected: The correct Grant Support information is given below:


This work was funded by National Natural Science Foundation of China grant 81472606, Chinese Ministry of Science and Technology grant (973 grant) 2011CB812401, and the Beijing Municipal Government.

Original article: Oncotarget. 22016; 7:3884-3896. DOI: https://doi.org/10.18632/oncotarget.6461.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26254